Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

Abstract Background Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC. In the second line, weekly or three-weekly irinotecan regimens have been adopted, however, the optimal dose and...

詳細記述

書誌詳細

出版年:	BMC Cancer
主要な著者:	Feride Yılmaz, Serkan Yaşar, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Deniz Can Güven, Arif Akyıldız, Elvin Chalabiyev, Burak Yasin Aktaş, Zafer Arık, Mustafa Erman
フォーマット:	論文
言語:	英語
出版事項:	BMC 2024-10-01
主題:	Irinotecan Small cell lung cancer Tolerability Bi-weekly administration
オンライン･アクセス:	https://doi.org/10.1186/s12885-024-12935-x